Nxera partners with Handok for Pivlaz distribution

Japanese drugmaker Nxera Pharma (TYO 4565) has entered into an exclusive supply and distribution agreement with Handok Pharmaceuticals to commercialize Pivlaz (clazosentan sodium) 150mg in South Korea.

Under the terms of the agreement, Nxera Pharma Korea (NPK) will provide drug product to Handok at an agreed price and Handok is exclusively responsible for the promotion, marketing, sales and distribution of Pivlaz in South Korea.

Until recently known as Sosei Group or Sosei Heptares, Nxera will receive a one-off upfront payment from Handok on signing of the agreement and is eligible for further commercial milestone payments plus sales coming from product supply.